A. Del Vecchio et al., Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions, TRANSFUSION, 41(6), 2001, pp. 803-808
BACKGROUND: Previous studies suggest that recombinant thrombopoietin (rTPO)
will increase platelet production in thrombocytopenic neonates. However, t
he target populations of neonates most likely to benefit should be defined.
Studies suggest that rTPO will not elevate the platelet count until 5 days
after the start of treatment. Therefore; the neonates who might benefit fr
om rTPO are those who will require multiple platelet transfusions for more
than 5 days. This study was designed to find means of prospectively identif
ying these patients.
STUDY DESIGN AND METHODS: A historic cohort study of all patients in the ne
onatal intensive care unit (NICU) at the University of Florida who received
platelet transfusions from January 1, 1997, through December 31, 1998, was
conducted.
RESULTS: Of the 1389 patients admitted to the NICU during the study period,
131 (9.4%) received platelet transfusions. Seventeen were treated with ext
racorporeal membrane oxygenation and were excluded from further analysis. O
f the remaining 114 patients, 55 (48%) received one transfusion and 59 (52%
) received more than one transfusion (21 had >4). None of the demographic f
actors examined predicted multiple platelet transfusions. However, two clin
ical conditions did; liver disease and renal insufficiency Neonates who rec
eived one platelet transfusion had a relative risk of death 10.4 times that
in neonates who received none (p = 0.0001). Neonates who received >4 plate
let transfusions had a risk of death 29.9 times that in those who received
no transfusions (p = 0.0001).
CONCLUSION: NICU patients with liver disease or renal insufficiency who rec
eive one platelet transfusion are likely to receive additional transfusions
. Therefore, these patients constitute a possible study population for a Ph
ase I/II rTPO trial.